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Abstract
OBJECTIVES: The aim was to investigate the safety and feasibility of the redesigned Engager™ transcatheter aortic valve implantation
(TAVI) system.
METHODS: Transapical aortic valve implantation with the Engager™ valve prosthesis was intended in 11 patients, and performed in 10.
Endpoints were deﬁned according to the valve academic research consortium recommendations for reporting outcomes of TAVI in clinical trials.
RESULTS: All 10 patients were implanted successfully. No devicerelated or delivery system complications like coronary obstruction or aortic dis-
section emerged. One patient (10%) died from non-device-related reasons at post-operative day 23 of multi-organ failure. The invasively mea-
sured peak-to-peak gradient after valve implantation was 7.1 ± 3.5 mmHg. In 90%, there was no or only trivial (≤grad I) aortic regurgitation due
to paravalvular leakage. In 10% of the patients, aortic regurgitation grade I–II was observed. At 30-day follow up, the mean gradient was 15.6 ±
4.9 mmHg, and no more than a mild transvalvular and paravalvular aortic regurgitation was seen as assessed by transthoracic echocardiography.
CONCLUSIONS: Application of the Engager™ TAVI system is safe and feasible. Prosthesis deployment in an anatomically correct position was
facilitated by the design of the valve prosthesis and was successful in all patients. No device or delivery-system-related complications emerged.
Safety and feasibility endpoints were met. Good results concerning the aortic valve performance after implantation and at 30-day follow up
were ascertained. These results encouraged the start of a European Pivotal trial including patients to date.
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INTRODUCTION
Several prostheses for transcatheter aortic valve implantation (TAVI)
have been developed [1–5]. A multicentre study with the ﬁrst gen-
eration of the Medtronic Engager™ Aortic Valve (formerly called
Ventor Embracer) prosthesis established the feasibility of implant-
ation into the correct anatomical position of this self-expandable
valve. However, following aortic dissections in 4 out of 30 patients
caused by non-covered commissural posts and a rigid straight de-
livery catheter, a redesign of the delivery system was completed [6].
A key feature of the redesigned system is a ﬂexible soft-tip
over-the-wire delivery-catheter that covers the entire prosthesis up
to the stage of deployment. Here, we describe the 30-day results
of the feasibility study with the new Engager™ TAVI system.
METHODS
Approval by competent authorities as well as the local ethical com-
mittees in three European centres was obtained for a multicentre
feasibility study in elderly patients (≥75 years of age) with severe
(mean gradient >40 mmHg, jet velocity >4.0 m/s, valve area ≤0.8
cm2 or indexed valve area ≤0.5 cm2/m2) symptomatic aortic sten-
osis who were considered to be at high risk (logistic EuroSCORE
≥15%) for surgical aortic valve replacement. All patients gave
written informed consent. The endpoints were deﬁned according
to the valve academic research consortium recommendations for
reporting outcomes of TAVI in clinical trials [7].
The valve
The Engager™ Aortic Valve bioprosthesis (Medtronic, Inc.,
Minneapolis, MN, USA), shown in Fig. 1, is a biological heart
valve prosthesis composed of three leaﬂets, cut from tissue-
ﬁxated bovine pericardium, sewn to a polyester sleeve and
mounted on a compressible and self-expanding Nitinol frame.
The stent assembly consists of a shaped main frame and a
support frame, which are coupled together so as to form the
commissural posts of the valve. Two types of sewing materials are
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used: polyester and expanded polytetraﬂuoroethylene. For this
study, the bioprosthesis was available in two sizes, labelled as 23
and 26 according to the diameter at the commissural outlet (in
mm); the Engager 23 and 26 have a total deployed frame length
of 25.5, and 27.5 mm, respectively. These two sizes are designed
to ﬁt an effective aortic annulus diameter by computed tomog-
raphy (CT) between 21 and 26.5 mm, typically corresponding to
an echocardiographic annulus diameter between 19 and 26. The
valve is sterilized and stored in a glutaraldehyde solution. To
achieve an anatomically correct position, a deﬁned height of im-
plantation and to minimize the risk of coronary obstruction, the
side arms ﬁxed at the main frame of the prosthesis are designed
to be placed into the sinuses of the aortic root.
Implant procedure
The procedures were performed from September 2010 to July
2011. All procedures were performed in a surgical hybrid suite and
with cardiopulmonary bypass on stand-by. The delivery system is
composed of a 29Fr (inner diameter) introducer and a ﬂexible de-
livery catheter with a 13Fr shaft, which form one integral unit
(Fig. 2). Prior to the procedure, the valve was crimped and
mounted onto the delivery system and handed pre-ﬂashed to the
operator. A temporary trans-venous pacemaker wire was inserted
for rapid pacing. A 6Fr femoral arterial sheath was inserted into
one femoral artery and a pigtail catheter was placed into the aortic
root for contrast aortography. A 6F introducer sheath was inserted
into one femoral vein and a guidewire placed in the right atrium to
establish access for fast cannulation in case conversion to extracor-
poreal circulation became necessary (safety precaution). Low-dose
heparin was given with a target activated clotting time of 250 s.
A standard transapical approach was applied. After exposure of the
apex, pledgeted purse string sutures were placed. The left ventricu-
lar apex was punctured with an 18G Seldinger-type needle and a
6Fr soft sheath was inserted. A standard soft guidewire was
advanced across the aortic arch into the descending aorta with
the help of a right coronary Judkins or Amplatz catheter and
exchanged for a 0.0035 super-stiff guidewire. The 6Fr sheath was
exchanged for a 14Fr sheath and a balloon valvuloplasty catheter,
selected according to the annulus diameter, was positioned and
balloon valvuloplasty was performed during a brief period of rapid
ventricular pacing. The delivery system with the mounted Engager
valve was then inserted over the guidewire and with the introducer
held ﬁxed at the desired depth, the delivery catheter was advanced
across the aortic valve under ﬂuoroscopic guidance. Commissural
alignment was performed using the technique of rotational posi-
tioning under ﬂuoroscopical control (Fig. 3). The Engager support
arms were then gradually exposed by controlling a blue rotating
knob at the handle. The support arms were then positioned in the
aortic sinuses by withdrawing the delivery catheter under
ﬂuoroscopical and tactile control. Before deployment, correct sub-
coronary positioning was veriﬁed by aortic root angiography.
Repositioning (if necessary with recapture of the support arms)
could be performed at this stage. After verifying that the desired
deployment position was achieved, a safety-button was unlocked,
allowing the uncovering of the commissural posts by further rotat-
ing the blue knob. Self-expandable deployment was controlled by
rotating a second (black) knob at the handle while holding the
support arms engaged against the valve. This was performed
under rapid ventricular pacing in seven patients and without
pacing in three. With the last turn of the knob, the device was
released. The delivery system was reconnected with the introducer
tube and the whole system including the guide wire, was removed
and the apex was closed with the purse string sutures. Valve pos-
ition and function were immediately assessed using angiographical
and echocardiographical imaging as well as by simultaneous
recording of the left ventricular and aortic pressure curves. The
pericardium was partially closed over the apex and a left lateral
chest tube inserted. Intercostal blockade was performed using a
local anaesthetic. The intercostal incision was closed in a standard
fashion. Femoral sheaths were removed. Post-operative device-
speciﬁc medical therapy consisted of aspirin 100 mg daily indeﬁn-
itely and clopidogrel 75 mg daily for at least 3 months.
Figure 1: Engager™ valve prosthesis.
Figure 2: Redesigned ﬂexible prosthesis delivery system with soft tip: loaded
device before implantation.
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RESULTS
Patient baseline characteristics
Eleven patients were brought to the operating room (OR) with
the intention to treat, and 10 patients underwent the implant-
ation procedure, all of them successfully. The patient ﬂowchart is
summarized in Fig. 4: the baseline characteristics of the 11
patients brought to the OR are summarized in Table 1. Mean age
was 82.5 ± 3.6 years (range from 76 to 88 years). Nine were
female. The majority of patients were in New York Heart
Classiﬁcation class III (eight patients) or IV (two patients) and one
patient had undergone previous cardiac surgery. Mean logistic
EuroSCORE was 24.6 ± 13.6% (range from 14.9 to 52.5%). Mean
aortic annulus diameter as assessed by transoesophageal echo-
cardiography was 21.0 ± 0.8 mm. Aortic annulus perimeter and
derived effective mean diameter by CT were 74 ± 2.3, and 23.6 ±
0.7 mm, respectively. Mean aortic valve pressure gradient was
49.3 ± 13.5 mmHg assessed by continuous-wave doppler.
Procedural details
Procedural details and outcomes are summarized in Table 2.
Accurate valve placement was achieved in all 10 implanted
patients. Mean ﬂuoroscopy time was 8.6 ± 2.5 min; 103 ± 32 ml
of contrast medium was used per procedure. Skin-to-skin time
was 94.5 ± 16.7 min. No device related or delivery-system-related
complications occurred in any of the 10 implanted patients.
Safety and efﬁcacy
Death within 30 days post-implant occurred in 2 of 11 patients
(18%) brought to the OR and 1 of the 10 patients (10%) in
whom the valve implantation was attempted.
One patient (logistic EuroSCORE 16.6%) experienced hypoten-
sion and cardiac arrest during insertion of the guidewire through
the apex to the aortic arch. The patient was stabilized through
the use of extracorporeal membrane oxygenation and balloon
valvuloplasty was performed. The procedure was aborted
without implantation of any prosthetic valve because the patient
deteriorated again and expired after a second attempt at
resuscitation.
Figure 3: Rotational positioning of the device. Commissural post with window is centred and its posterior position is veriﬁed by observing its movement to the
left of the image upon mild clockwise rotation.
Figure 4: Patient flowchart.
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The second patient (logistic EuroSCORE 48.9%) became
haemodynamically unstable upon introduction of the balloon
valvuloplasty sheath, and experienced cardiac arrest. The patient
was resuscitated and the Engager™ valve bioprosthesis was suc-
cessfully deployed. The patient was transferred to the ICU in a
stable condition, but had a complicated post-operative course
(including respiratory insufﬁciency requiring reintubation, tra-
cheal perforation, third degree atrioventricular (AV) block requir-
ing pacemaker implantation, renal insufﬁciency requiring dialysis
and bowel ischaemia requiring resection), and ultimately died
on post-implant day 23 of multi-organ failure. There were no
strokes or myocardial infarctions during the ﬁrst 30 days after
implantation. One patient (10%) with chronic renal insufﬁciency
required dialysis in the early post-operative period.
Prosthetic valve performance
The invasively measured peak-to-peak gradient after valve im-
plantation was 7.1 ± 3.5 mmHg. In nine of the implanted
patients, there was no or only trivial (grad I or less) aortic regur-
gitation due to paravalvular leak. In one patient, aortic regurgita-
tion grade I–II was observed. There were no cases of aortic
insufﬁciency greater than grade II. At 30-day follow up, average
mean aortic gradient was 15.6 ± 4.9 mmHg (one patient who
may have beneﬁted from a post-dilatation had a mean gradient
of 24 mmHg; all other values ranged between range 8.0 and 17
mmHg). No more than mild transvalvular and paravalvular aortic
regurgitation was assessed by transthoracic echocardiography
(Table 3).
Prosthetic valve-associated complications
Two of 10 implanted patients (20%) required permanent pace-
maker implantation for complete atrioventricular block. One
patient developed complete atrioventricular block for a short
period of time followed by resuscitation, and during the follow-
ing day appeared to have stable sinus rhythm with AV-block
grade I. One patient with known episodes of atrial ﬁbrillation
pre-implantation developed atrial ﬁbrillation requiring electro-
cardioversion at Day 5. No coronary obstructions or aortic dis-
sections occurred, no undesired mitral interference, or any other
prosthesis-related adverse events were observed and none of
the implanted prostheses was explanted.
DISCUSSION
The purpose of this feasibility study was to assess the safety and
clinical performance of the re-designed Engager™ TAVI system
prior to commencing a multicentre pivotal study. Ten of 11
patients who were considered high risk for conventional aortic
valve replacement have been successfully implanted through a
Table 2: Procedural details
Characteristic FIM* [6] (n = 30) Feasibility
(n = 10)
Aortic annulus diameter
(mm)
21.8 ± 1.4 21.0 ± 0.8
Accurate device placement
(patients)
29 (97%) 10 (100%)
Used prosthesis size (patients)
23 mm 30 (100%, only
available size)
4 (40%)
26 mm 6 (60%)
Skin-to-skin time (min) 74 ± 16 94.5 ± 16.7
Contrast medium volume
(ml)
130 ± 58 103 ± 32
Fluoroscopy time (min) 7.5 ± 2.6 8.6 ± 2.5
*FIM: first-in-man.
Table 3: Haemodynamic parameters pre- and post-
implantation
Pre-procedural Post-procedural 30-day
follow-up
Mean aortic valve
gradient (mmHg)
49.3 ± 13.5 15.6 ± 4.9
Invasive peak-to-peak
gradient (mmHg)
7.1 ± 3.5
Mean LVOT** gradient
(mmHg)
3.1 ± 3 2.2 ± 1.0
Peak aortic valve
velocity (m/s)
4.5 ± 0.5 2.7 ± 0.5
Annulus diameter
(mm)
22 ± 1
Peak LVOT** velocity
(m/s)
1.0 ± 0.2 1.0 ± 0.2
Velocity time integral
(cm)
21.7 ± 6.1 20.4 ± 5.1
Aortic regurgitation*
None 1
0–I 9
I 8
II 1
LVOT: left ventricular outflow tract.
*Data for one patient is missing.
Table 1: Baseline characteristics of patients brought
to the OR
Characteristic No. of patients Percentage
n 11
Age (years) 82.5 ± 3.6
Female 9 80
Logistic EuroSCORE (%) 24.6 ± 13.6
New York Heart Classification
II 1 9
III 8 73
IV 2 18
Chronic pulmonary disease 5 45
Impaired renal function 0 0
Neurological dysfunction 1 9
Previous cardiac surgery 1 9
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transapical approach with the Medtronic Engager™ bioprosthesis
using the new delivery system. One patient died in the OR
before valve implantation was attempted and 1 of the 10
implanted patients died on post-procedure day 23 after experi-
encing multiple serious adverse events resulting in an as-treated
mortality rate of 10%. The ﬂexible over-the-wire delivery system
adapted well to the aortic anatomy, and allowed for safe and
quick implantation without evidence of aortic injury or any
other delivery-system-related complications. No patient experi-
enced a stroke after implantation and until 30 days of follow up.
No vascular complication occurred in our patient population.
These results conﬁrm the ﬁndings of other trials reporting a low
incidence of major vascular complications [8, 9] for the transapi-
cal access. Although the number of patients in this feasibility
study is small, the current results suggest that the redesign of the
delivery system, as a ﬂexible, fully covered over-the-wire system,
has effectively corrected the root cause of the aortic dissections
observed in the ﬁrst-in-man study.
At the end of the procedure, 9 of 10 patients had no more
than grade I perivalvular regurgitation, and none had grade II or
more. No patient was documented with more than mild trans-
valvular or paravalvular regurgitation by colour ﬂow Doppler
echocardiography at 30-day follow-up. Different values for the
mean transprosthetic gradients were obtained with two different
methods and under different haemodynamic conditions: the
peak-to-peak pressure gradient during general anaesthesia and
the transthoracic echocardiographically measured gradient
based on ﬂow velocity and calculated with the modiﬁed
Bernoulli equation. The geometry of the support arms facilitates
predictable deployment of the prosthesis into an anatomical
correct positioning with a deﬁned height of implantation,
making the procedure both intuitive and reliable. Adverse events
like valve dislocation and coronary obstruction as described for
other prostheses [8] can potentially be avoided by the design,
and were indeed not observed. The incidence and type of
reported serious adverse events could be primarily attributed to
the study’s patient population with a mean logistic EuroSCORE
of 24.5%.
In conclusion, the current results of the Engager™ feasibility
study demonstrated the successful deployment of the Engager™
bioprosthesis into an anatomically correct position without peri-
operative delivery system-related complications using the rede-
signed Engager™ transapical catheter delivery system. As a result,
patients are currently being enrolled into the multicentre,
multinational prospective pivotal study, in order to conﬁrm the
safety and clinical performance of the Engager™ bioprosthesis in
a larger patient population.
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